Company: TAK
Filing Date: 2025-10-30
Form Type: 6-K
Source: 0001395064-25-000152
Chunk: 19

Company: TAKEDA PHARMACEUTICAL CO LTD
Filing Date: 2025-10-30
Form: 6-K
Chunk 19
---
 period ended September 30, 2025.

#### Core

#### EPS
Core EPS was JPY 279 (JPY -31 and -10.0% AER, -10.8% CER).

<div align='center'>8</div>

Takeda Pharmaceutical Company Limited (4502)

Earnings Report ( Kessan Tanshin ) for the Six-month

Period Ended September 30, 2025 (Consolidated)

### (2) Consolidated Financial Position
|                   |     | As of | March 31, 2025 |     |     | September 30, 2025 |     | Change |       | Billion JPY |
|:------------------|:----|:------|---------------:|:----|:----|-------------------:|:----|:-------|------:|:------------|
| Total Assets      |     |       |       14,248.3 |     |     |           14,470.3 |     |        | 222.0 |             |
| Total Liabilities |     |       |        7,312.4 |     |     |            7,338.6 |     |        |  26.2 |             |
| Total Equity      |     |       |        6,936.0 |     |     |            7,131.7 |     |        | 195.7 |             |

#### Assets
Total Assets as of September 30, 2025 were JPY 14,470.3 billion ( JPY +222.0 billion). Cash and cash equivalents increased (JPY +296.4 billion). Goodwill increased ( JPY +107.3 billion ) mainly due to the effect of foreign currency translation. Inventories increased ( JPY +82.1 billion ) primarily driven by higher work-in-process and finished goods related to PDT products and ENTYVIO, as well as the effect of foreign currency translation. These increases were partially offset by the decrease of Intangible Assets ( JPY -332.3 billion) m ainly due to amortization .

#### Liabilities
Total Liabilities as of September 30, 2025 were JPY 7,338.6 billion ( JPY +26.2 billion ). Total Bonds and Loans were JPY 4,645.3 billion*, which increased ( JPY +130.1 billion ) mainly due to the effect of foreign currency and the issuances of